Viewing Study NCT00034476



Ignite Creation Date: 2024-05-05 @ 11:24 AM
Last Modification Date: 2024-10-26 @ 9:07 AM
Study NCT ID: NCT00034476
Status: COMPLETED
Last Update Posted: 2006-07-19
First Post: 2002-04-29

Brief Title: A Phase IIb Study to Determine the Efficacy and Safety of the Study Drug in Patients With Severe Sepsis
Sponsor: Eli Lilly and Company
Organization: Eli Lilly and Company

Study Overview

Official Title: A Phase IIb Study to Determine the Efficacy and Safety of the Study Drug in Patients With Severe Sepsis
Status: COMPLETED
Status Verified Date: 2006-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to determine whether the administration of the study drug is effective in increasing the chance of survival in patients with severe sepsis Patients entered into this study will be randomly assigned to one of two treatment groups Patients in each treatment group will be given either the study drug or placebo as a continuous infusion directly into the bloodstream through a catheter placed in one of the patients veins

The study drug is an investigational drug that is still in development It has been studied in approximately 30 healthy subjects approximately 30 patients with either kidney failure or arthritis and approximately 600 patients with severe sepsis Patient participation in this study will last for about one month
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
J4A-MC-EZZI None None None